1. Immunohistochemical staining patterns of canine meningiomas and correlation with published immunophenotypes.
- Author
-
Barnhart KF, Wojcieszyn J, and Storts RW
- Subjects
- Animals, Brain Neoplasms metabolism, Brain Neoplasms pathology, Central Nervous System Neoplasms metabolism, Central Nervous System Neoplasms pathology, Dog Diseases metabolism, Dogs, Female, Glial Fibrillary Acidic Protein metabolism, Immunohistochemistry veterinary, Immunophenotyping, Keratins metabolism, Male, Meningioma metabolism, Meningioma pathology, Phosphopyruvate Hydratase metabolism, S100 Proteins metabolism, Synaptophysin metabolism, Vimentin metabolism, Brain Neoplasms veterinary, Central Nervous System Neoplasms veterinary, Dog Diseases pathology, Meningioma veterinary
- Abstract
This study examined immunohistochemical staining patterns for several meningioma variants involving either the brain or spinal cord of dogs. Formalin-fixed, paraffin-embedded tissue from 15 tumors was obtained. The selected tumor group included seven meningothelial, three transitional, two malignant (anaplastic), one myxoid, one papillary, and one osteomatous meningiomas. Tumors were evaluated for reactivity to the following six immunohistochemical markers: vimentin, pancytokeratin, glial fibrillary acidic protein (GFAP), S100, neuron-specific enolase (NSE), and synaptophysin. Vimentin expression was detected in all meningiomas, and 14 of 15 tumors demonstrated intense vimentin staining in more than 50% of the neoplastic cells. Pancytokeratin expression was present in 11 of 15 neoplasms; however, positive staining frequently was focal and often involved a small percentage of the neoplastic cells. GFAP expression was detected in a single, anaplastic meningioma. Although expression of NSE and S100 was detected in 12 of 25 meningiomas, the intensity of the staining and the percentage of positive neoplastic cells was highly variable. Synaptophysin was uniformly negative. These results will help to establish immunohistochemical profiles for meningiomas that will improve our ability to correctly differentiate these neoplasms of meningeal origin from central nervous system tumors originating from other sites.
- Published
- 2002
- Full Text
- View/download PDF